398489-26-4CC(C)(C)OC(=O)N1CC(=O)C1VMKIXWAFFVLJCK-UHFFFAOYSA-N398489-26-4DTXSID90364022Sicherheitsangaben dienen nur zur Orientierung und ersetzen weder das Sicherheitsdatenblatt (SDB) des Lieferanten noch geltende Vorschriften oder eine fachliche Bewertung.
Danger
H302 (97.8%): Harmful if swallowed [Warning Acute toxicity, oral]
P261, P264, P264+P265, P270, P271, P280, P301+P317, P302+P352, P304+P340, P305+P354+P338, P317, P319, P321, P330, P332+P317, P362+P364, P403+P233, P405, and P501 (click each P-code to see the statement)
Aggregated GHS information provided per 45 reports by companies from 8 notifications to the ECHA C&L Inventory. Each notification may be associated with multiple companies.
Verwenden1-Boc-3-azetidinone can be used for the preparation of antibacterial aminoglycoside analogs.
Verwendentert-Butyl 3-oxoazetidine-1-carboxylate(1-Boc-3-azetidinone) is a currently common organic intermediate. It is a key intermediate for preparing various medicaments. It can be used for preparing Janus kinase 3(JAKS), which is a useful target for immunosuppression and transplant rejection, and can be used for treating inflammatory disorders, autoimmune disorders, cancer and other diseases; also useful in the preparation of a second class of HCV protease inhibitors useful in the treatment of HCV genotype 1 infection; can also be used for preparing novel aminoglycoside compounds with antibacterial activity; bicyclic himbacine (himbacine) derivatives can be prepared which are useful as antagonists of the protease activated receptor-1 (PAR-1) and are predicted to be cannabis (CB2) receptor inhibitors, useful for the treatment of secondary prevention of Acute Coronary Syndrome (ACS), myocardial infarction or thrombotic stroke or peripheral arterial disease; bicyclic azacyclobenzylamine derivatives, such as pyridopyrimidines, can be prepared that modulate the activity of phospho-inositol 3-kinase (P13K) and are useful in the treatment of diseases associated with P13K, including, for example, inflammatory disorders, immune-based disorders, cancer, and other diseases.